- Case Report
- Open Access
Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome
© Shigemura et al; licensee BioMed Central Ltd. 2011
Received: 28 February 2011
Accepted: 13 July 2011
Published: 13 July 2011
Systemic juvenile idiopathic arthritis (sJIA) is a systemic inflammatory disease characterized by arthritis, spiking fever and a skin rash that is frequently complicated by macrophage activation syndrome (MAS), a life-threatening disorder. We report a 22-month-old girl with sJIA who developed severe MAS but was successfully treated with corticosteroids, cyclosporin A, and non-steroidal anti-inflammatory drugs by monitoring serum IL-18 levels. IL-18 is an extremely useful cytokine for monitoring the activity of sJIA and MAS, and serum IL-18 can be used as an indicator for the effectiveness of treatment and the decision to discontinue therapy.
Systemic juvenile idiopathic arthritis (sJIA) is a disease of unknown etiology characterized by arthritis and systemic symptoms starting before the age of 16. The most characteristic feature at onset is spiking fever, which is often associated with a skin rash . Macrophage activation syndrome (MAS) is a life-threatening complication of chronic rheumatic diseases during childhood that is seen most commonly in sJIA. Symptoms of MAS include fever, hepatosplenomegaly, lymphoadenopathy, profound depression of all 3 blood cell lines, abnormal liver function, intravascular coagulopathy, and central nervous system dysfunction. MAS is thought to be caused by the activation and uncontrolled proliferation of T lymphocytes and macrophages, resulting in an unrestricted release of inflammatory cytokines . Given that MAS can follow a rapidly fatal course, prompt diagnosis by its clinical and laboratory features and immediate therapeutic intervention are critical for survival .
IL-18 was originally described as an INF-γ-inducing factor produced mainly by activated macrophage lineage cells . IL-18 stimulates a variety of inflammatory responses, enhances proliferation and activity of T cells and natural killer (NK) cells, and shifts Th-cell balance towards a Th1 response . In combination with IL-12, IL-18 strongly stimulates T lymphocytes, NK cells, and macrophages to produce IFN-γ . Recently, highly elevated serum levels of IL-18 have been reported in patients with sJIA [6, 7].
In the present case, we investigated the utility of serum IL-18 as a marker for disease activity in a patient with sJIA complicated by MAS.
A 22-month-old girl was transferred to our hospital from a rural hospital with a 2-week history of fever, rash, mild arthritis in bilateral wrist, knee, and ankle joints, and pain involving the entire body despite therapy with intravenous antibiotics and gamma globulin. On admission, her transaminases, LDH, CRP, sIL-2R and ferritin levels were all elevated (AST 139 U/l, ALT 56 U/l, LDH 1,110 U/l, CRP 10.72 mg/dl, sIL-2R 8,440 U/ml and ferritin 10,284 ng/ml). She had thrombocytopenia and coagulation disturbance; her platelet count, fibrinogen levels, and fibrinogen-fibrin degradation product (FDP-DD) levels were 108,000/μl, 211.9 mg/dl, and 24.8 μg/ml (normal <1.0 μg/ml), respectively. Her fever had changed from spiking to a persistent fever 2 days prior to admission to our hospital. Evaluation for bacterial and viral infections, including the Epstein-Barr virus, were negative. Bone marrow aspirates were negative for dysplasia, but were positive for hemophagocytosis.
Four weeks after the methylprednisolone pulse therapy and before a dose reduction of the steroids, the girl's fever returned with a mild coagulation disturbance. Her serum FDP-DD level was 13.6 μg/ml. Her transaminases, LDH, CRP, sIL-2R, and ferritin levels were not increased at the time (AST 48 U/l, ALT 22 U/l, LDH 401 U/l, CRP 6.73 mg/dl, sIL-2R 585 U/ml, and ferritin147 ng/ml). On the basis of these clinical and laboratory findings, we made a diagnosis to recurring sJIA without definite MAS. At that time, IL-1 or IL-6 antagonists were not available in Japan. However, as soon as treatment with ibuprofen was initiated without increasing steroid doses, the patient's condition dramatically improved. One and a half years later, all medications were tapered off, and patient has shown no signs of recurrence for two years since cessation of treatment.
Monitoring serum IL-18
Serum concentrations of IL-18 were determined using a commercially available kit (Human IL-18 enzyme-linked immunoassay kit; BML, Nagoya, Japan)(Figure 1). On admission to our hospital, serum IL-18 was extremely high (284,900 ng/ml, normal range 100-400 ng/ml) and serum IL-6 was elevated at 72.7 pg/ml. Immediately following three courses of steroid pulse therapy, serum IL-18 decreased to 22,064 ng/ml, but remained elevated (over 10,000 ng/ml) from then on. At the time of the fever flare-up, serum IL-18 had increased again to 35,235 ng/ml. After the patient dramatically improved following treatment with ibuprofen, serum IL-18 and IL-6 were 2,000 ng/ml and less than 10 pg/ml, respectively. After that, IL-18 levels gradually improved to normal with serum IL-6 remaining below 10 pg/ml. At that time, we judged we could safely discontinue medication for her sJIA. IL-18 levels of under 400 ng/ml have since persisted for two years without any symptoms.
This report presents a child with sJIA complicated by MAS who was treated successfully while being monitored for serum IL-18 levels at clinically important stages.
Although MAS has been considered a rare complication of sJIA, it is likely more common than previously thought [8–10]. MAS also accounts for a significant proportion of the morbidity and mortality seen in sJIA. Since MAS is a serious condition that can follow a rapidly fatal course, prompt recognition and immediate therapeutic intervention are critical. For the treatment of sJIA complicated by MAS, corticosteroids, cyclosporin A, and non-steroidal anti-inflammatory drugs (NSAIDs) are reported useful. Although methotrexate and tumor necrosis factor antagonists, such as infliximab, are often only partially effective against sJIA, the anti-interleukin 6 receptor antagonist tocilizumab or IL-1 receptor antagonist anakinra have shown good clinical efficacy in small open-label studies of sJIA and adult Still's Disease [11–14]. The use of anakinra to treat the MAS complication of sJIA has been reported . NSAIDs and systemic corticosteroids have historically been the initial mainstays of treatment for sJIA  and were administered to our patient. There have not been prior reports of NSAIDs treatment of MAS. Since sJIA did relapse without significant MAS at the time of the fever flare-up, it appeared that ibuprofen was effective for treating sJIA in this case. With the current availability of tocilizumab or anakinra in Japan for sJIA, we employ these drugs as treatment of sJIA recurrence or when disease activity is uncontrollable. We anticipate that these new drugs, tocilizumab and anakinra, may decrease serum IL-18 when decreasing disease activity in sJIA/MAS.
The difficulty in diagnosing sJIA or sJIA complicated by MAS emphasizes the need for more sophisticated diagnostic tools. Given that serum IL-18 is often increased in sJIA and spikes sharply when complicated by MAS, IL-18 may be useful to diagnose MAS following sJIA [6, 7]. IL-18 is also helpful in the differentiation of sJIA and Kawasaki disease because of low levels of serum IL-18 in the latter . In contrast, serum IL-6 levels were found to be high both in sJIA and Kawasaki disease, but did not increase further when sJIA patients developed MAS . In our case, we failed to assay serum IL-18 during early state sJIA prior to MAS because serum was not available. However, we were able to confirm the recurrence of sJIA through the elevation of IL-18 levels when her high fever recurred with a minor coagulation disturbance.
The precise criteria for discontinuation of sJIA medication are an important issue for clinicians. Shimizu et al. reported that serum IL-18 levels, but not IL-6, neopterin or CRP, were significantly different in both active and inactive disease states of sJIA without MAS, demonstrating the utility of IL-18 in evaluating disease activity of sJIA . Accordingly, we discontinued medication when IL-18 levels fell to less than 400 ng/ml, and the patient has subsequently been in remission for 2 years to date.
This case report suggests that evaluating serum IL-18 levels in children with sJIA may be very useful in assessment and treatment of the sJIA as well as with the sJIA complication MAS.
- Ravelli A, Martini A: Juvenile idiopathic arthritis. Lancet. 2007, 369: 767-778. 10.1016/S0140-6736(07)60363-8.View ArticlePubMedGoogle Scholar
- Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, Viola S, Martini A: Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Journal of Pediatrics. 2005, 146: 598-604. 10.1016/j.jpeds.2004.12.016.View ArticlePubMedGoogle Scholar
- Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K: Cloning of a new cytokine that induces IFN-g production by T cells. Nature. 1995, 78: 88-91.View ArticleGoogle Scholar
- Gracie JA, Robertson SE, McInnes IB: Interleukin-18. Journal of Leukocyte Biology. 2003, 73: 213-224. 10.1189/jlb.0602313.View ArticlePubMedGoogle Scholar
- Yoshimoto T, Takeda H, Tanaka T, Ohkusu K, Kawashima S, Okamura H, Akira S, Nakanishi K: IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. 1998, 161: 3400-3407.PubMedGoogle Scholar
- Maeno N, Takei S, Nomura Y, Imanaka H, Hokonohara M, Miyata K: Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease. Arthritis Rheum. 2002, 46: 2539-2541. 10.1002/art.10389. comment on the article by Kawashima et alView ArticlePubMedGoogle Scholar
- Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, Toma T, Ohta K, Kasahara Y, Yachie A: Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology. 2010, 49: 1645-1653. 10.1093/rheumatology/keq133.View ArticlePubMedGoogle Scholar
- Sawhney S, Woo P, Murray KJ: Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Archives of Disease in Childhood. 2001, 85: 421-426. 10.1136/adc.85.5.421.PubMed CentralView ArticlePubMedGoogle Scholar
- Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA: The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007, 56: 965-971. 10.1002/art.22416.View ArticlePubMedGoogle Scholar
- Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, Ramanan AV: Anakinra treatment for systemic onset juvenile idiopathic arthritis. Rheumatology. 2008, 47: 555-556.View ArticlePubMedGoogle Scholar
- Behrens EM, Beukelman T, Paessler M, Cron RQ: Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007, 34: 1133-811.PubMedGoogle Scholar
- Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, Wythe H, Thomson D, Kishimoto T: Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005, 7: 1281-1288. 10.1186/ar1826.View ArticleGoogle Scholar
- Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC: Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. Arthritis and Rheumatism. 2010, 63: 45-555.Google Scholar
- Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ: Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology. 2011, 50: 417-419. 10.1093/rheumatology/keq218.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.